, Volume 28, Issue 5, pp 347-349
Date: 23 Sep 2012

Single Technology Appraisal at the UK National Institute for Health and Clinical Excellence

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

The UK National Institute for Health and Clinical Excellence (NICE) has been given a range of responsibilities by government to provide guidance to the NHS in England and Wales on questions of clinical effectiveness and resource allocation. NICE’s programme of technology appraisal has raised particular interest internationally as an application of evidence- and analysis-based decision making regarding the use of new pharmaceuticals and other interventions in the NHS.

For the first 6 years of the programme, the evidence and analysis (the technology assessment phase) supporting decisions were supplied by manufacturers and an academic assessment group. In response to criticism regarding the speed and expense of this process, most notably during the House of Commons Health Select Committee’s review,[1] NICE introduced its Single Technology Appraisal (STA) process in late 2005. Although the old system (Multiple Technology Appraisal [MTA]) remains for some appraisals (e.g. periodic reviews of